Heartbeam stock initiated with Buy rating at Roth/MKM on cardiac device potential
PositiveFinancial Markets

Heartbeam has received a Buy rating from Roth/MKM, highlighting the company's promising potential in the cardiac device market. This endorsement is significant as it suggests confidence in Heartbeam's innovative technology, which could lead to improved patient outcomes and growth in the healthcare sector. Investors may see this as a positive signal for future performance.
— Curated by the World Pulse Now AI Editorial System







